Concise takeaways

• Authors provide the first experimental evidence that galectin‑3 (gal3) and galectin‑3–binding protein (gal3bp) localize to thrombus-relevant compartments and promote venous thrombosis (VT) in an IVC stasis model; gal3 correlates with thrombus size and with vein‑wall IL‑6 expression, and recombinant gal3 increases VT in WT but not IL‑6–deficient mice, implicating an IL‑6–dependent prothrombotic mechanism (mouse model; n=244) Deroo et al., Blood 2015 (gal3/gal3bp in VT)
• Independent mechanistic work (in vitro) shows galectin‑3 can interact with/activate integrins (αIIbβ3/αvβ3/α5β1), offering a plausible cell‑adhesion/inflammatory mechanism linking gal3 to thrombosis and platelet/leukocyte‑endothelial adhesion Gal3–integrin activation (in vitro)

Visual, evidence‑first critique: "The role of galectin‑3 and galectin‑3–binding protein in venous thrombosis"

Fig A — Thrombus growth (raw reported data)

Source: thrombus weights reported in the paper (non‑VT and VT at 3, 6, 48 h). The authors collected n=5 per timepoint for the time course and report increases from 0.0210 g (3 h) to 0.0402 g (48 h) Deroo et al. thrombus weights

Fig B — Vein-wall gal3 and IL‑6 (reported gene expression values)

Reported qRT‑PCR: gal3 increased from 0.0305 (non‑VT) to 0.0915 (VT, 48 h); IL‑6 increased from 0.00054 (non‑VT) to 0.02382 (VT, 48 h). Authors report a strong positive correlation between gal3 and IL‑6 expression (r^2=0.81) Deroo et al. gal3–IL6 qRT-PCR

Fig C — Relationship: vein‑wall gal3 expression vs thrombus weight (reported correlation)

Authors report a statistically significant positive correlation between gal3 expression in the vein wall and thrombus weight (r^2 = 0.77, P < .05) across timepoints and conditions, suggesting an association between local gal3 upregulation and thrombus growth Deroo et al. gal3–thrombus correlation

Critical appraisal — strengths, limits, and interpretation

• Strengths (solid): large mouse cohort (n=244 reported overall), multiple complementary methods (WB, qRT‑PCR, IF/IHC, functional rescue with rGal3, genetic KO of Lgals3 and IL‑6, and antibody targeting of gal3bp) that converge on a consistent story: gal3 upregulation, gal3/gal3bp localization at vein‑wall/leukocyte interface, IL‑6 induction, and reduced thrombosis when gal3 or gal3bp is inhibited Deroo et al. strengths
• Key mechanistic link — plausibility: authors demonstrate that rGal3 raises vein‑wall IL‑6 and that rGal3 fails to increase thrombus weight in IL‑6 KO mice, supporting that gal3→IL‑6 is required for the prothrombotic effect in this model. This is strengthened by literature showing Gal3 can induce cytokines and by recent mechanistic work linking Gal3 to integrin activation (adhesion) that plausibly explains increased leukocyte/platelet adhesion to endothelium (integrin αIIbβ3 activation is thrombosis‑relevant) Deroo et al. gal3→IL6 functional linkGal3–integrin mechanistic study
• Limitations & blind spots:
  • The IVC ligation stasis model predominantly reflects endothelial/tissue‑factor driven thrombosis in a non‑flow context; generalizing to flow‑dependent human DVT requires caution (authors note this) Deroo et al. model limitation
  • Human data are limited: the paper provides a small, pilot human sample showing elevated circulating gal3bp in acute VT, but no large clinical cohort or diagnostic performance measures vs D‑dimer are given — so biomarker claims remain preliminary Deroo et al. human pilot limitations
  • Mechanistic chain is supported but not fully resolved: while gal3→IL‑6 is necessary in this model, upstream triggers of gal3 increase and downstream cell types (platelet intrinsic vs platelet–leukocyte complexes vs endothelial activation) remain incompletely dissected; in vivo integrin activation by Gal3 is suggested by in vitro work but not demonstrated in the mouse VT model (gap in direct in vivo integrin assays) Gal3–integrin evidence needs in vivo validation
  • Possible technical caveats: western blots show multiple gal3 bands (monomer/multimer/cleavage products). Authors hypothesize roles for multimers and cleavage fragments, but functional differences of these species in thrombosis were not systematically tested; antibody specificity, platelet translational hypotheses, and microparticle sources need further corroboration by proteomics or mass spec in future work Deroo et al. gal3 isoforms observed

Where this paper moves the field

1. Introduces gal3/gal3bp as plausible inflammation‑linked promoters of VT with experimental functional proof in mice.
2. Provides a testable mechanistic axis: Gal3 (multimerization/adhesivity) → endothelial/leukocyte/platelet interactions → IL‑6 induction → thrombus growth.
3. Generates translational hypotheses: (a) blocking gal3bp/gal3 reduces VT; (b) circulating gal3bp may be an acute VT biomarker; (c) integrin antagonism of Gal3 binding might be explored therapeutically (links to recent integrin activation in vitro work) Gal3–integrin therapeutic implication

Recommendations (next decisive experiments)

• Use flow (non‑stasis) venous thrombosis models or ferric chloride endothelial injury models to test whether gal3 effects generalize beyond stasis-driven IVC ligation.
• Directly test in vivo whether Gal3 engages platelet integrin αIIbβ3 and endothelial αvβ3 during VT (e.g., proximity ligation assays, intravital microscopy with fluorescent Gal3, or use of site‑2 antagonists shown to block activation in vitro) — that would close a major mechanistic gap cited here Gal3–integrin antagonists (in vitro)
• Expand human cohorts: prospective sampling at symptom onset, paired D‑dimer and gal3/gal3bp measurements, and receiver‑operator analyses to assess diagnostic value and confounders (age, cardiac disease, infection).
• Isolate and functionally test gal3 isoforms (monomer vs multimer vs cleavage fragments) by recombinant expression to determine which species drive adhesion vs cytokine induction.

Summary assessment (concise)

This is a careful, multi‑modal preclinical study that convincingly demonstrates galectin‑3 and galectin‑3–binding protein are associated with and promote venous thrombosis in the mouse IVC stasis model, likely via IL‑6‑dependent inflammatory mechanisms and leukocyte recruitment. The translational claims (biomarker, therapeutic target) are plausible but require larger human cohorts and in vivo validation of molecular mechanisms (e.g., Gal3→integrin activation) before clinical translation. The paper is high quality for a preclinical mechanistic study, though model and sample limitations moderate generalizability.

Selected citations (primary)

• Deroo et al., Blood 2015
• Gal3–integrin activation (in vitro)
• Proteomics: gal3bp in human clots

Quick practical guidance for researchers

1. If you plan follow-up in vivo studies, include non‑stasis DVT models and test Gal3/site‑2 integrin antagonists in vivo.
2. For biomarker work, design a prospective ED cohort with immediate sampling and matched D‑dimer to estimate sensitivity/specificity and confounders.
3. Perform proteomic/MS validation of gal3 species on platelets and microparticles to dissect monomer/multimer/cleaved forms functionally.